Identifying biomarkers for lung inflammation after cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the side effects of chemoradiotherapy followed by immunotherapy in patients with non-small cell lung cancer, focusing on the occurrence of lung inflammation known as pneumonitis. Researchers will collect blood, stool, and saliva samples, along with lung function data, to create a comprehensive database that correlates treatment with adverse effects. The study aims to identify early signs of lung function problems, potentially leading to quicker interventions and improved patient outcomes. Additionally, it will explore the impact of treatment on sleep quality and gut health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Newly-diagnosed NSCLC patients who will be undergoing concurrent chemotherapy and radiotherapy (XRT) followed by immune checkpoint inhibitors (CPI) therapy with durvalumab, as per the PACIFIC trial
* Willing to undergo all treatment and evaluation at MD Anderson Cancer Center (MDACC)
* Has access to a smartphone with the ability to transmit data via wireless connection or through their personal cellular plan
* Able and willing to perform home spirometry (HS) weekly without absolute contraindications to performing spirometry

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Ajay Sheshadri — M.D. Anderson Cancer Center

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Atezolizumab after surgery to prevent NSCLC from coming back

  This trial tests whether giving atezolizumab (with or without hyaluronidase) for one year after complete surgery helps prevent NSCLC from returning compared with observation.

  Recruiting at 145 sites Phase 3 National Cancer Institute (NCI) · Anaheim, California and 144 other locations · NCT07388524

• Patient experiences and preferences for IV versus subcutaneous immunotherapy in non-small cell lung cancer

  This survey asks people with non-small cell lung cancer who are receiving immune checkpoint inhibitors whether they prefer IV treatment or subcutaneous injections at the hospital or at home.

  Recruiting at 2 sites University of Southern California · Los Angeles, California and 1 other locations · NCT07339254

• Telisotuzumab vedotin combined with osimertinib for progressive, incurable non-small cell lung cancer

  This trial tests whether adding the antibody-drug telisotuzumab vedotin to ongoing osimertinib can shrink tumors or slow growth in adults with progressive, incurable non-small cell lung cancer who have EGFR mutations.

  Recruiting Phase 2 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07323641

• Targeted post-surgery radiation plus standard therapy for NSCLC with remaining nodal cancer

  This phase II trial tests whether adding intensity-modulated post-operative radiation therapy to standard chemotherapy or immunotherapy helps people with non-small cell lung cancer and remaining lymph node cancer after surgery.

  Recruiting at 121 sites Phase 2 Alliance for Clinical Trials in Oncology · Jonesboro, Arkansas and 124 other locations · NCT07293247

• Using blood and tissue biomarkers to guide immunotherapy and later treatment choices in advanced non-small cell lung cancer

  This trial tests whether blood and tumor biomarkers can predict who will respond to first-line PD‑1/PD‑L1 immunotherapy and help pick better second-line treatments for people with stage IIIB–IV non‑small cell lung cancer.

  Recruiting at 13 sites Phase 2 City of Hope Medical Center · Goodyear, Arizona and 12 other locations · NCT07288034

• Psilocybin-assisted therapy for major depression in people with non-small cell lung cancer

  This phase II trial tests whether a single oral dose of psilocybin combined with psychotherapy can reduce moderate-to-severe depression in adults with non-small cell lung cancer.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07216404

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.